News
Candesartan is beneficial in heart failure with mildly reduced ejection fraction
Analysis of data from the CHARM study showed that in patients with heart failure with mildly reduced ejection fraction (HFmrEF 0.40–0.49), candesartan compared to placebo reduces the risk of death from cardiovascular (CV) causes or hospitalization for heart failure similarly to patients with reduced ejection fraction (HFrEF < 0.40).
COVID-19 and MS: Do You Know the Risk Factors? What the American Registry Analysis Showed
An article published in the March issue of the prestigious journal JAMA Neurology summarizes the…
Fatigue in Multiple Sclerosis: What Can Teriflunomide Do?
An article by French authors published in January this year in the journal Multiple Sclerosis and…
Long-term effect of the triple combination of perindopril, indapamide, and amlodipine on left ventricular hypertrophy in hypertension
A recent open-label interventional study aimed to describe the long-term effect of a fixed triple…
Myths Accompanying Therapy of Arterial Hypertension
Arterial hypertension is among the most common yet most underestimated diseases in the adult…
Effect of Discontinuing Inhaled Corticosteroids in Patients with COPD in Real Clinical Practice
Inhaled corticosteroids are prescribed to patients with COPD to prevent disease exacerbation.…
Impact of the COVID-19 Pandemic on People with Schizophrenia Spectrum Disorders
The COVID-19 pandemic has a far-reaching impact on the physical and mental health of the global…
Why Are Mucolytics Beneficial for Patients with COPD?
Part of the clinical picture of chronic obstructive pulmonary disease (COPD) includes mucus…
Dual therapy improves not only lung function but also quality of life in COPD patients
Chronic obstructive pulmonary disease (COPD) reduces the quality of life of patients and is one of…
Therapy with Cyclosporine in the Context of the Coronavirus Pandemic
The rapid spread of the SARS-CoV-2 virus and the associated COVID-19 disease pandemic raises…